Webcast- San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes

This accredited continuing education activity “Webcast-San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes”, is recorded from the live course held between 02/03-02/04/2023. 

If you participated in the live course titled "San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes" from 02/03 to 02/04/2023 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is recorded content from that course  from 02/03-02/04/2023.  However, you may enroll in this activity to review the contents. 

The recorded lectures and subsequent discussions feature leading experts in lung cancer who provide a comprehensive overview of the implications of actionable molecular alterations in lung cancer. 

The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with thoracic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted therapies for thoracic oncology. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. 

The symposium will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:

  •  Neoadjuvant and adjuvant treatment of non-small cell lung cancer (NSCLC) including specific roles of immune-checkpoint inhibitors, targeted therapy, and chemotherapy.
  • Role of different platforms, including next-generation sequencing and PD-L1 assessment to identify treatment options in NSCLC.
  • Appropriate use of systemic therapy in small cell lung cancer (SCLC)
  • Novel approaches to the treatment of mesothelioma and thymic malignancies
  • Trends, challenges, controversies, and limitations of precision oncology approaches and targeted therapies in the management of thoracic malignancies.

REGISTRATION FEES:

This activity is free for all.

Target Audience

  • Medical Oncologists
  • Surgeons
  • Radiation Oncologists,
  • Pathologists Oncology Fellows
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Review frequent molecular abnormalities in NSCLC, and appropriate testing and treatment
  2. Outline efficacy and toxicities of immune checkpoint inhibitors, targeted therapy, and other chemotherapy agents in management of management of NSCLC
  3. Identify the role of neoadjuvant and adjuvant systemic therapy options in curative-intent treatment of NSCLC, including the role of chemotherapy, immune checkpoint inhibitors and targeted therapy.
  4. Incorporate appropriate sequencing of treatment options in patients with mesothelioma and thymic malignancies.
  5. Integrate emerging evidence in precision oncology into testing and treatment paradigms for treatment of thoracic malignancies.
Course summary
Available credit: 
  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
Course opens: 
02/17/2023
Course expires: 
02/03/2024
Cost:
$0.00

This educational activity features recorded videos from the live webcast titled - San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes held 2/3-2/4 2023.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.

Session 1: Molecular Mysteries in Cancer:  Controversies in Biomarker Assessment 

Moderator: Dara Aisner, MD, PhD

16 minutes: Case Intro:  The Case of the Missing ALK- Dara Aisner, MD, PhD

16 minutes: Optimization in Tissue Acquisition and Pathologic Assessment- George Cheng, MD, PhD

16 minutes Systemic Management of ALK-Rearranged NSCLC- Sai-Hong Ignatius Ou MD,PhD

16 minutes: Clinical Utility of Circulating Tumor DNA in NSCLC - Aditya Sarvaria, MD

18 minutes: Case Panel: Molecular Mysteries in Cancer:  Controversies in Biomarker Assessment - Session Speakers

Session 2: Early Stage NSCLC

Moderator: Misako Nagasaka, MD, PhD

16 minutes: Advances in Neoadjuvant Treatment in NSCLC – Misako Nagasaka, MD, PhD

15 minutes: Surgical Management after Neoadjuvant Treatment in NSCLC- Hari Keshava, MD

18 minutes: Radiotherapy in Early Stage NSCLC- Arya Amini, MD

16 minutes: Panel discussion Early Stage NSCLC - Session speakers

Session 3: New Horizons in Locally Advanced NSCLC

Moderator: Salma Jabbour, M.D., FASTRO

16 minutes: RT and Immunotherapy Synergy in Unresectable NSCLC- Salma Jabbour, MD, FASTRO

17 minutes: MRD in Locally Advanced NSCLC- Aadel Chaudhuri, MD PhD

13 minutes: Immunotherapy Combinations: Building on the PACIFIC Paradigm- Kathryn Gold, MD

16 minutes: Panel discussion: New Horizons in Locally Advanced NSCLC - Session speakers

Session 4: Use of Immunotherapy in Metastatic NSCLC

Moderator: Narjust Florez, MD     

26 minutes: Systemic Immunotherapy Options in Metastatic Lung Cancer - Narjust Florez, MD 

18 minutes: Oligometastatic Radiotherapy Options-  Steven Lin, MD, PhD

15 minutes: Biomarkers for Immunotherapy use in NSCLC- Sai-Hong Ignatius Ou, MD, PhD

6 minutes: Panel discussion: Use of Immunotherapy in Metastatic NSCLC - Session Speakers

Session 5: Targeted Therapy in NSCLC

Moderator: Jack West, MD  

16 minutes: Advances in Targeted Therapy in metastatic NSCLC - Andy (Sew-Chung) Jang, MD

17 minutes: Use of Targeted Therapy in Localized NSCLC - Jonathan Riess MD, MS

17 minutes: RT and targeted therapy: CNS and Extra-Cranial Considerations- Jona Hattangandi-Gluth, MD PhD

18 minutes: Case Panel: Targeting Resistance in NSCLC - Session Speakers   

Session 6: Mesothelioma and Thymic Malignancies

Moderator: Kavitha Ramchandran, MD

17 minutes: Multimodal Treatment for Malignant Pleural Mesothelioma (MPM): Surgical Treatment Options in 2023- Jeffrey Velotta, MD

16 minutes: Advances in Treatment in Thymic Malignancies: Kavitha Ramchandran, MD

16 minutes: Systemic Immunotherapy Approaches to Mesothelioma- Matthew Gubens MD, MS

16 minutes: Role of RT in Thymoma and Thymic Malignancies- Stephen Chun, MD

9 minutes: Mesothelioma and Thymic Malignancies Case Panel discussion- Session Speakers

Session 7: Small Cell Lung Cancer 

Moderator: Nagla Abdel Karim, MD 

14 minutes: Advances in Immunotherapy in SCLC - Nagla Abdel Karim, MD

13 minutes: Management of Refractory SCLC - Ana Velazquez Manana, MD

16 minutes: Role of RT in SCLC - Percy Lee, MD

Concluding remarks – Drs. Kristin Higgins and Sandip Patel

  

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTEREST:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

COURSE DIRECTOR(S)

Kristin Higgins, MD has a financial relationship (Professional Services) with Genentech; a financial relationship (Professional Services) with Janssen Pharmaceuticals; a financial relationship (Professional Services) with Astra Zeneca; a financial relationship (Grant Or Contract) with RefleXion Medical; a financial relationship (Grant Or Contract) with Jazz Pharmaceuticals.

Sandip Patel, MD has a financial relationship (Grant Or Contract) with BMS; a financial relationship (Grant Or Contract) with Pfizer; a financial relationship (Grant Or Contract) with AstraZeneca/MedImmune; a financial relationship (Grant Or Contract) with Roche/Genentech; a financial relationship (Grant Or Contract) with Merck.

 

MODERATOR(S)

Nagla Abdel Karim, MD, Ph.D. has a financial relationship (Other) with BMS, Exelixis, Pfizer, and AstraZeneca and a financial relationship (Professional Services) with Jazz, Regeneron, and Amgen.

Dara Aisner, MD, Ph.D. has a financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Abbvie; a financial relationship (Professional Services) with Genentech; a financial relationship (Professional Services) with Loxo/Eli Lilly; a financial relationship (Professional Services) with Sanofi Genzyme; financial relationship (Professional Services) with Takeda.

Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist has a financial relationship (Professional Services) with Neogenomics; a financial relationship (Professional Services) with AstraZeneca; a financial relationship (Professional Services) with Janssen; a financial relationship (Professional Services) with DSI; a financial relationship (Professional Services) with BMS; a financial relationship (Professional Services) with BMS; a financial relationship (Professional Services) with Merck; a financial relationship (Professional Services) with Pfizer.

Salma Jabbour, M.D. Professor & Vice Chair of Clinical Research and Faculty Development has a financial relationship (Professional Services) with Novocure; a financial relationship (Professional Services) with Advarra; a financial relationship (Professional Services) with Radialogica; a financial relationship (Professional Services) with Merck & Co, Inc; a financial relationship (Professional Services) with IMX Medical.

Misako Nagasaka has a financial relationship (Professional Services) with Novartis; a financial relationship (Professional Services) with Genentech; a financial relationship (Professional Services) with Janssen; a financial relationship (Professional Services) with Daiichi Sankyo; a financial relationship (Professional Services) with Lilly; a financial relationship (Professional Services) with Takeda; a financial relationship (Professional Services) with Pfizer; a financial relationship (Professional Services) with Caris Life Sciences; a financial relationship (Travel) with AnHeart Therapeutics; a financial relationship (Professional Services) with AstraZeneca; a financial relationship (Professional Services) with EMD Serono; a financial relationship (Professional Services) with Mirati; a financial relationship (Professional Services) with Blueprint Medicine.

Kavitha Ramchandran, MD has a financial relationship (Other) with Varian Medical Systems; a financial relationship (Other) with Group well; a financial relationship (Other) with Pathomiq; a financial relationship (Other) with Curio Science.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA has a financial relationship (Independent contractor) with Merck; a financial relationship (Independent contractor) with Amgen; a financial relationship (Independent contractor) with Genentech/Roche; a financial relationship (Independent contractor) with Takeda; a financial relationship (Independent contractor) with AstraZeneca; a financial relationship (Independent contractor) with Regeneron; a financial relationship (Independent contractor) with Mirati.

SPEAKER(S)

Nagla Abdel Karim, MD, Ph.D. has a financial relationship (Professional Services) with Jazz, Regeneron, and Amgen; a financial relationship (Other) with BMS, Exelixis, Pfizer, and AstraZeneca.

Dara Aisner, MD, Ph.D. has a financial relationship (Professional Services) with Loxo/Eli Lilly; a financial relationship (Professional Services) with Sanofi Genzyme; a financial relationship (Professional Services) with Takeda; a financial relationship (Professional Services) with AstraZeneca; a financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with Genentech.

Arya Amini, MD has no relevant financial relationships to disclose at this time.

Aadel Chaudhuri, MD Ph.D. has a financial relationship (Independent contractor) with Daiichi Sankyo; a financial relationship (Independent contractor) with Guidepoint; a financial relationship (Other) with Illumina; a financial relationship (Independent contractor) with DeciBio; a financial relationship (Stock) with LiquidCell Dx; financial relationship (Independent contractor) with Tempus Labs; financial relationship (Independent contractor) with AlphaSights; financial relationship (Stock) with Droplet Biosciences; financial relationship (Independent contractor) with Roche; financial relationship (Independent contractor) with AstraZeneca; financial relationship (Stock Options) with Geneoscopy.

George Cheng, MD Ph.D.hD has a financial relationship (Professional Services) with Intuitive; a financial relationship (Professional Services) with Olympus; a financial relationship (Professional Services) with Boston Scientific; a financial relationship (Professional Services) with Cook; financial relationship (Professional Services) with Siemens; financial relationship (Professional Services) with Pulmonx; financial relationship (Professional Services) with Medtronic; financial relationship (Professional Services) with ERBE.

Stephen Chun has a financial relationship (Independent contractor) with Curio Science, Inc; a financial relationship (Travel) with ViewRay, Inc; financial relationship (Independent contractor) with AstraZeneca, PLC.

Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist has a financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Neogenomics; financial relationship (Professional Services) with DSI; a financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Pfizer; financial relationship (Professional Services) with Merck.

Kathryn Gold has a financial relationship (Independent contractor) with AstraZeneca; a financial relationship (Independent contractor) with Regeneron.

Matthew Gubens has a financial relationship (Independent contractor) with Surface; a financial relationship (Independent contractor) with AstraZeneca; a financial relationship (Independent contractor) with Gemzyme; a financial relationship (Independent contractor) with Sanofi; a financial relationship (Independent contractor) with Genentech/Roche; financial relationship (Independent contractor) with Cardinal Health; financial relationship (Independent contractor) with iTeos; financial relationship (Independent contractor) with BMS; financial relationship (Independent contractor) with Guardant.

Jona Hattangadi-Gluth has no relevant financial relationships to disclose at this time.

Salma Jabbour, M.D. Professor & Vice Chair of Clinical Research and Faculty Development has a financial relationship (Professional Services) with Advarra; financial relationship (Professional Services) with Radialogica; financial relationship (Professional Services) with IMX Medical; financial relationship (Professional Services) with Merck & Co, Inc; financial relationship (Professional Services) with Novocure.

Andy Jang, Assistant Professor of Medicine has no relevant financial relationships to disclose at this time.

Hari Keshava, MD, MS has no relevant financial relationships to disclose at this time.

Percy Lee, MD has a financial relationship (Professional Services) with Varian; financial relationship (Professional Services) with ViewRay; financial relationship (Grant Or Contract) with AstraZeneca; a financial relationship (Professional Services) with Roche; a financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Genentech.

Steven Lin, MD, Ph.D. has a financial relationship (Grant Or Contract) with STCube Pharmaceuticals; a financial relationship (Professional Services) with AstraZeneca; a financial relationship (Professional Services) with XRAD Therapeutics; a financial relationship (Grant Or Contract) with Nektar Therapeutics; financial relationship (Grant Or Contract) with Beyond Spring Pharmaceuticals.

Misako Nagasaka has a financial relationship (Professional Services) with Daiichi Sankyo; a financial relationship (Professional Services) with Lilly; financial relationship (Professional Services) with Takeda; a financial relationship (Professional Services) with AstraZeneca; a financial relationship (Professional Services) with Pfizer; financial relationship (Professional Services) with Caris Life Sciences; financial relationship (Travel) with AnHeart Therapeutics; financial relationship (Professional Services) with EMD Serono; financial relationship (Professional Services) with Mirati; financial relationship (Professional Services) with Blueprint Medicine; financial relationship (Professional Services) with Novartis; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Janssen.

Sai-Hong Ou has no relevant financial relationships to disclose at this time.

Kavitha Ramchandran, MD has a financial relationship (Other) with Varian Medical Systems; a financial relationship (Other) with Group well; a financial relationship (Other) with Pathomiq; a financial relationship (Other) with Curio Science.

Jonathan Riess, MD, MS has a financial relationship (Professional Services) with Blueprint; a financial relationship (Professional Services) with Jazz Pharmaceuticals; a financial relationship (Professional Services) with Boehringer Ingelheim; a financial relationship (Professional Services) with Daiichi Sankyo; financial relationship (Independent contractor) with Genentech; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with EMD Serano; financial relationship (Professional Services) with Turning Point; financial relationship (Professional Services) with Regeneron; financial relationship (Professional Services) with Biodesix; financial relationship (Professional Services) with Bayer; financial relationship (Professional Services) with Boehringer Ingelheim; financial relationship (Professional Services) with Novartis; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Beigene.

Aditya Sarvaria, MD has no relevant financial relationships to disclose at this time.

Ana Velazquez Manana, MD MSc has a financial relationship (Stock) with Corbus Pharmaceuticals; a financial relationship (Independent contractor) with Astra Zeneca.

Jeffrey B. Velotta, MD, FACS has no relevant financial relationships to disclose at this time.

This activity is supported by an independent medical education grant from the following companies:

  • Exact Sciences
  • Novartis Pharmaceuticals Corporation

Important Information about Claiming CME for this activity:

If you participated in the live course titled "San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes" from 02/03 to 02/04/2023 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is recorded content from that course from 02/03-02/04/2023.

 

 

Available Credit

  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all.